Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee
MWN-AI** Summary
Windtree Therapeutics, Inc. (OTCID: WINT), based in Warrington, Pennsylvania, has announced a potentially lucrative opportunity arising from its global license agreement related to acute pulmonary treatments aimed at addressing respiratory distress syndrome (RDS) in premature infants. Executed in August 2022, this agreement could yield up to $78.9 million in development, regulatory, and commercial milestone payments, in addition to low double-digit royalties on sales.
The company's portfolio includes treatments such as SURFAXIN®—an FDA-approved synthetic drug aimed at preventing RDS in high-risk premature infants—and lyophilized lucinactant, along with AEROSURF®, a combination of drug and device designed to administer aerosolized KL4 surfactant noninvasively. These treatments seek to offer innovative solutions for infants suffering from RDS, a serious condition stemming from underdeveloped lungs in preterm babies.
Jed Latkin, the CEO of Windtree, expressed his support for the development efforts outlined by their licensing partner, emphasizing the urgent need for new and effective treatments for RDS worldwide. He noted that any milestone and royalty payments received would be non-dilutive, which could significantly aid in advancing the company's current corporate strategy towards profitability.
As his team gears up to share further information about potential milestone payments and their expected timing, Windtree Therapeutics remains focused on becoming a revenue-generating entity through its diverse array of therapeutic candidates. The promising developments in their acute pulmonary franchise represent a strategic move toward improving the management of RDS while enhancing Windtree's financial positioning.
MWN-AI** Analysis
Windtree Therapeutics, Inc. (OTCID: WINT) has announced a promising development regarding its licensing agreement for treatments aimed at addressing Respiratory Distress Syndrome (RDS) in premature infants. The amended agreement includes potential milestone payments of up to $78.9 million along with low double-digit royalties from its licensee, who will cover all costs associated with development and commercialization. This strategic collaboration positions Windtree to benefit financially from the innovations in pulmonary treatments.
Investors should consider the implications of these milestones and royalty payments as they represent a non-dilutive funding mechanism that could sustain the company’s corporate strategy without requiring additional equity financing. Given that RDS remains a critical health challenge for premature infants, the therapeutic products—lyophilized lucinactant and AEROSURF®—target an urgent need within a niche but vital healthcare market, which could enhance the revenue-generating capacity of Windtree Therapeutics.
The presence of a dedicated licensing partner provides an additional layer of reassurance for investors, as the partner's commitment to advancing RDS treatments could expedite the timeline for achieving these milestones. Updates regarding the expected timing of these payments will be crucial for potential investors, who should monitor Windtree's communications closely.
As Windtree shifts its focus towards revenue generation, the successful rollout of the licensed treatments, alongside potential financial inflows, marks a favorable outlook. Investors may want to keep an eye on market conditions and advancements in treatment development that could further influence Windtree's stock performance.
In summary, Windtree Therapeutics is positioned to leverage its licensing agreement as a pathway to potential growth and funding stability. Investors should remain informed of the execution of this strategic collaboration as it progresses.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties
The licensed treatments include SURFAXIN ® , lyophilized lucinactant and AEROSURF ® (a drug and device combination)
The franchise is intended to treat premature infants with respiratory distress syndrome (RDS)
Windtree will communicate more information about milestone payments it may receive from its licensing partner and the future timing of those potential payments
WARRINGTON, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it may receive license agreement payments from its licensee for renewed development work in the Company’s licensed acute pulmonary treatments. The amended and restated global license agreement was executed in August, 2022. The agreement includes potential milestone payments up to $78.9 million and up to low double digit royalties. The license partner is responsible for all costs of development and commercialization.
RDS occurs in preterm infants when the lung is not fully developed with natural lung surfactant and may require surfactant therapy to sustain life. The risk of a premature infant developing RDS is related to the gestational age, with the earliest age at highest risk.
“Windtree has been informed by its licensing partner about its acute pulmonary treatment development plan and we are supportive for these activities,” said Jed Latkin, Chief Executive Officer of Windtree. “Around the world, RDS remains as a serious condition that needs innovation. Potential milestone and royalty payments to Windtree would be non-dilutive and could contribute to funding our current corporate strategy.”
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company with several divisions and focused on becoming a revenue generating company with future profitability.
About Lyophilized Lucinactant and AEROSURF ®
Lyophilized lucinactant is an investigational synthetic peptide (KL4 surfactant) containing drug product that is being developed to improve the management of RDS in premature infants who may not have fully developed natural lung surfactant and may require surfactant therapy to sustain life. AEROSURF® (lucinactant for inhalation) is a drug/device combination designed to deliver aerosolized KL4 surfactant noninvasively using our proprietary ADS technology and potentially may meaningfully reduce the use of invasive endotracheal intubation and mechanical ventilation.
About SURFAXIN
Surfaxin (generic name: lucinactant) was a synthetic drug used to prevent respiratory distress syndrome (RDS) in high-risk premature infants. Unlike earlier treatments derived from animal lungs, Surfaxin was created in a lab to mimic the natural lung fluid that helps air sacs stay open. The drug was approved by the U.S. Food and Drug Administration in 2012. However, it was discontinued by the manufacturer and is no longer available in the United States.
Forward Looking Statements
The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: risks related to the Company’s ability to begin its environmental services business and manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
[email protected]
FAQ**
How does Windtree Therapeutics Inc. WINT plan to utilize the potential $78.9 million in milestone payments to ensure the long-term growth and sustainability of the company?
What specific timelines does Windtree Therapeutics Inc. WINT anticipate for the milestone payments from its licensing partner, and how might these payments affect the company's capital structure?
Can Windtree Therapeutics Inc. WINT provide more detail on the development plan for the acute pulmonary treatments and their expected impact on premature infants with RDS?
With the potential for low double-digit royalties, how does Windtree Therapeutics Inc. WINT expect to manage its operational budget while relying on third-party funding for development and commercialization?
**MWN-AI FAQ is based on asking OpenAI questions about Windtree Therapeutics Inc. (NASDAQ: WINT).
NASDAQ: WINT
WINT Trading
-12.12% G/L:
$0.116 Last:
1,921,610 Volume:
$0.132 Open:
